Search
forLearn
5 / 801 resultslearn taurine
learn TeraCeutic™
learn thiamin
learn Tumeric
Research
5 / 79 results
research LP-161 Tjalma syndrome (Pseudo-Pseudo Meigs Syndrome): polyserositis with increased CA-125 in patients with systemic lupus erythematosus
Tjalma Syndrome is a rare condition in people with lupus, causing fluid buildup and high CA-125 levels, but not due to tumors.
research Evidence-based clinical guidelines for treatment: Acne – Androgenetic alopecia
research Autologous platelet-rich plasma (PRP) for the treatment of pattern hair loss: A review
research Serum levels of vitamin D3 in patients with hair loss
Many people with hair loss have low vitamin D levels.
research Comparison of androgenic alopecia distribution among type 2 diabetes and healthy women in Isfahan city: a brief report
Type II diabetes is not linked to hair loss in women.
Community Join
5 / 1000+ resultscommunity The end of minoxidil and fin/dut regime
New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.
community Topical T3 study - 1000% Growth. Anyone tried it?
The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.
community TGF-Beta. Good or Bad? Help for treatment investment
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
community Taurine supplements work for hair growth?
The conversation discusses taurine supplements for hair growth, highlighting their potential to reduce DHT and improve hair health. A user comments that people often try alternatives to finasteride.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.